🟢 Definium Therapeutics is trading 8.90% up today after DT120 reduced anxiety symptoms in second trial

Definium Therapeutics is trading at $42.50 (+8.90%) after DT120 reduced generalized-anxiety symptoms in a second successful late-stage trial.

• The 245-patient study showed a 9.8-point HAM-A improvement versus 4.7 points for placebo after 12 weeks.
• The results strengthen the company’s path toward a regulatory filing in 2027 despite broader market weakness.